Hereditary spherocytosis (HS) is a genetic disorder that affects the shape and function of the red blood cells. It is one of the most common inherited red blood cell disorders, affecting about one in every 5,000 people. HS is caused by mutations in one of several genes that are responsible for the production of proteins that are essential for the structure and function of red blood cells. The mutations can result in a variety of symptoms, including anemia, jaundice, fatigue, and enlarged spleen. The genetic basis of HS has been studied for many years, but the exact cause of the disorder has remained a mystery. In recent years, genetic testing has become more common and has allowed researchers to identify the specific genes involved in HS. This has enabled them to better understand the underlying genetic mechanisms of the disorder and to develop more effective treatments. In this article, we will explore the genetic basis of HS and discuss how genetic testing can help to diagnose and treat the disorder.
Hereditary spherocytosis (HS) is an inherited disorder that affects the shape and function of red blood cells. Red blood cells are normally round and flexible, allowing them to move easily through the bloodstream. In HS, the red blood cells become rigid and spheroid, or “spherocytic”, which makes them more susceptible to damage. As a result, the red blood cells are more likely to be destroyed by the spleen, leading to a decrease in their number and anemia. The most common symptoms of HS include anemia, jaundice, fatigue, and enlarged spleen. Anemia is caused by the decreased number of red blood cells, which leads to a decrease in the amount of oxygen that is delivered to the body’s tissues. Jaundice is caused by the increased breakdown of red blood cells, which leads to an accumulation of bilirubin, a yellow pigment, in the skin and eyes. Fatigue is caused by the decreased delivery of oxygen to the body’s tissues due to the decreased number of red blood cells. Enlarged spleen is caused by the increased destruction of red blood cells by the spleen.
The genetic basis of HS has been studied for many years, but the exact cause of the disorder has remained a mystery. In recent years, genetic testing has become more common and has allowed researchers to identify the specific genes involved in HS. The primary gene involved in HS is the ANK1 gene, which is responsible for the production of a protein called ankyrin-1. This protein is essential for the structure and function of red blood cells. Mutations in the ANK1 gene can lead to a decrease in the amount of ankyrin-1 produced, which can cause the red blood cells to become rigid and spheroid. In addition to the ANK1 gene, other genes have been identified that are involved in HS. These include the EPB42 gene, which is responsible for the production of a protein called erythrocyte membrane protein band 4.2, and the SPTB gene, which is responsible for the production of a protein called spectrin beta chain. Mutations in these genes can also lead to a decrease in the amount of proteins produced, which can cause the red blood cells to become rigid and spheroid.
Genetic testing is the primary method for diagnosing HS. A blood sample is taken and sent to a laboratory for testing. The laboratory will look for mutations in the ANK1, EPB42, and SPTB genes. If mutations are found, then a diagnosis of HS can be made. Treatment for HS is aimed at reducing the symptoms of the disorder. Treatment options include medications to reduce the destruction of red blood cells, blood transfusions to replace the lost red blood cells, and surgery to remove the spleen. In some cases, a bone marrow transplant may be recommended to replace the defective red blood cells with healthy ones.
Hereditary spherocytosis is a genetic disorder that affects the shape and function of red blood cells. It is caused by mutations in one of several genes that are responsible for the production of proteins that are essential for the structure and function of red blood cells. Genetic testing is the primary method for diagnosing
1.
Belgian Algorithm Reshapes Endometrial Cancer Care
2.
ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer
3.
Nuclear missile workers are contracting cancer: They blame the bases
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology
1.
Understanding SVR Normal Range: A Guide to Achieving Optimal Health
2.
Consensus Recommendations for Healthy Hematologic Aging
3.
The Role of Alanine Aminotransferase in Liver Health and Disease
4.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
5.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation